ABSTRACT
Adoptively transferred allergic encephalomyelitis can be inhibited by various phosphosugars, particularly mannose-6-phosphate. The sugar specificity suggests that inhibition may be due to depletion of lymphocyte cell-surface lysosomal enzymes, which are essential for the passage of lymphocytes across the vascular endothelium and the entry of lymphocytes into the central nervous system parenchyma.
Subject(s)
Autoimmune Diseases/drug therapy , Encephalomyelitis, Autoimmune, Experimental/drug therapy , Hexosephosphates/therapeutic use , Mannosephosphates/therapeutic use , Animals , Autoimmune Diseases/immunology , Dose-Response Relationship, Drug , Encephalomyelitis, Autoimmune, Experimental/immunology , Female , Immunity, Cellular , Lymphocytes/enzymology , Lymphocytes/immunology , Male , Mannosephosphates/administration & dosage , RatsABSTRACT
It was established in experiments on 24 dogs with ligated interventricular branch of the left coronary artery that hexosophosphate (0.5 and 1 ml/kg intravenously) increases the collateral coronary blood flow and myocardial contractility against the background of a decrease in the lactate content in blood draining from the ischemic zone. Preliminary injection of hexosophosphate to rabbits increases the respiratory control in mitochondria from the ischemic myocardium. Drip intravenous hexosophosphate (100 ml) infusion to patients in the acute period of myocardial infarction reduced significantly sigma ST in precardiac leads and reduced the lactic acid content in venous blood. In 7.6% of cases hexosophosphate caused arrest or abatement of the pain syndrome.
Subject(s)
Coronary Disease/drug therapy , Energy Metabolism/drug effects , Hexosephosphates/therapeutic use , Acute Disease , Aged , Animals , Collateral Circulation/drug effects , Dogs , Drug Evaluation , Drug Evaluation, Preclinical , Female , Heart/drug effects , Humans , Male , Middle Aged , Myocardial Infarction/drug therapy , Myocardium/metabolism , Rabbits , Time FactorsABSTRACT
The authors' experience with the clinical use of an antihypoxic substnace--hexosophosphate representing the complex of tetraphosphoric glucose and fructose esters is reported. The substance was studied experimentally on 20 dogs and clinically in 126 patients with diseases of vessels, abdominal organs and the kidneys. A positive effect was gained in peroral and intravenous use of the substance both with theaim of preparative management of patients to be subjected to major surgery and postoperatively. HP, being a readily absorbed energetic substance, renders a normalizing effect on the hemodynamics, the bowel activity, improves general patients'state, that is of special value in patients whose state is aggravated by concomitant lesions.
